ArticleCancer medicine2024

An international multicenter study comparing COVID-19 omicron outcomes in patients with hematological malignancies treated with obinutuzumab versus rituximab.

Tali Shafat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.